HK1052300B - 具有保護神經系統活動功能的7-hydroxyepiandrosterone - Google Patents

具有保護神經系統活動功能的7-hydroxyepiandrosterone

Info

Publication number
HK1052300B
HK1052300B HK03104578.9A HK03104578A HK1052300B HK 1052300 B HK1052300 B HK 1052300B HK 03104578 A HK03104578 A HK 03104578A HK 1052300 B HK1052300 B HK 1052300B
Authority
HK
Hong Kong
Prior art keywords
hydroxyepiandrosterone
neuroprotective activity
hydroxy
steroids
oxo
Prior art date
Application number
HK03104578.9A
Other languages
English (en)
Other versions
HK1052300A1 (en
Inventor
Ashley Ker Pringle
Lars Eric Sundstrom
Ernst Wulfert
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Publication of HK1052300A1 publication Critical patent/HK1052300A1/xx
Publication of HK1052300B publication Critical patent/HK1052300B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK03104578.9A 2000-06-29 2003-06-26 具有保護神經系統活動功能的7-hydroxyepiandrosterone HK1052300B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0016022A GB2363983A (en) 2000-06-29 2000-06-29 Protection against neuronal damage using 7-hydroxyepiandrosterone
PCT/GB2001/002937 WO2002000225A1 (en) 2000-06-29 2001-06-29 7-hydroxyepiandrosterone having neuroprotective activity

Publications (2)

Publication Number Publication Date
HK1052300A1 HK1052300A1 (en) 2003-09-11
HK1052300B true HK1052300B (zh) 2009-01-30

Family

ID=9894707

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03104578.9A HK1052300B (zh) 2000-06-29 2003-06-26 具有保護神經系統活動功能的7-hydroxyepiandrosterone

Country Status (24)

Country Link
US (2) US7718639B2 (zh)
EP (1) EP1294382B1 (zh)
JP (1) JP4942905B2 (zh)
KR (1) KR100786284B1 (zh)
CN (1) CN100459980C (zh)
AT (1) ATE401897T1 (zh)
AU (2) AU2001267709B2 (zh)
CA (1) CA2414584C (zh)
CY (1) CY1108773T1 (zh)
CZ (1) CZ299676B6 (zh)
DE (1) DE60134979D1 (zh)
DK (1) DK1294382T3 (zh)
ES (1) ES2310182T3 (zh)
GB (1) GB2363983A (zh)
HK (1) HK1052300B (zh)
HU (1) HU227152B1 (zh)
IL (2) IL153541A0 (zh)
NO (1) NO327959B1 (zh)
PL (1) PL200699B1 (zh)
PT (1) PT1294382E (zh)
RU (1) RU2307654C2 (zh)
SI (1) SI1294382T1 (zh)
WO (1) WO2002000225A1 (zh)
ZA (1) ZA200300085B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2378898A (en) * 2001-08-14 2003-02-26 Hunter Fleming Ltd Prophylactic and therapeutic use of hydroxysteroids
US20040138187A1 (en) * 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
HUE036410T2 (hu) * 2006-11-21 2018-07-30 Asarina Pharma Ab Pregnán és androsztán szteroidok alkalmazása CNS rendellenességek kezelésére szolgáló gyógyszerkészítmény elõállítására
EP2147673A1 (en) 2006-11-30 2010-01-27 Hunter-Fleming Limited Modulation of prostaglandin/cyclooxygenase metabolic pathways
GB0623971D0 (en) * 2006-11-30 2007-01-10 Hunter Fleming Ltd Modulation of prostaglandin/cyclooxygenase metabolic pathways

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU243975A (en) 1974-10-14 1982-06-30 Schering Ag Process for obtaining 7-hydroxyestradiols
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
US5707983A (en) 1990-08-29 1998-01-13 Humanetics Corporation Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes
US5212167A (en) 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
US5846963A (en) 1995-06-07 1998-12-08 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
WO1994020111A1 (en) 1993-03-09 1994-09-15 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5387583A (en) * 1993-04-20 1995-02-07 Loria; Roger M. Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof
US5877169A (en) 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5976850A (en) 1994-10-19 1999-11-02 University Of Edinburgh Hippocampus-associated proteins; DNA sequences coding therefor and uses thereof
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
HUP9901138A3 (en) 1995-06-06 1999-11-29 Cocensys Inc Irvine Neuroactive steroids of the androstane and pregnane series
JP4313435B2 (ja) 1995-07-24 2009-08-12 トラスティーズ オブ ボストン ユニバーシティー プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
GB2317826B (en) * 1995-08-29 1999-12-15 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
JP2000511404A (ja) 1996-04-09 2000-09-05 ビー・テイー・ジー・インターナシヨナル・リミテツド 神経精神、免疫又は内分泌障害を治療するための７α置換ステロイドの使用
DE69733655T2 (de) 1996-08-27 2006-04-27 Praecis Pharmaceuticals, Inc., Cambridge beta-AMYLOID PEPTIDAGGREGATION REGULIERENDE PEPTIDE MIT D-AMINOSÄUREN
FR2760362B1 (fr) 1997-03-10 2000-08-11 Vitasterol Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles
WO1998043647A1 (en) * 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
GB9708716D0 (en) * 1997-04-29 1997-06-18 Imperial College Chronic heart failure
WO1999015179A1 (en) 1997-09-25 1999-04-01 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
AU1387399A (en) 1997-11-10 1999-05-31 Vyrex Corporation Probucol esters and uses thereof
WO1999026630A1 (en) * 1997-11-24 1999-06-03 University Of Florida Research Foundation, Incorporated Testosterone inhibitors and use for the protection of neurons
GB9726569D0 (en) 1997-12-16 1998-02-11 Univ Southampton Neuroprotective agents
AU3467699A (en) * 1998-04-14 1999-11-01 Pharmadigm, Inc. Method for reducing central nervous system impairment
FR2786102B1 (fr) * 1998-11-20 2001-02-16 Monique Vincens Utilisation de sulfate de dehydroepiandrosterone pour augmenter le nombre de recepteurs nmda chez un mammifere
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20030083231A1 (en) 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
DK1226155T3 (da) 1999-11-02 2007-09-10 Bayer Schering Pharma Ag 18-nor-steroider som selektivt virksomme östrogener
GB0003524D0 (en) 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders

Also Published As

Publication number Publication date
ZA200300085B (en) 2004-04-21
RU2307654C2 (ru) 2007-10-10
CN100459980C (zh) 2009-02-11
ES2310182T3 (es) 2009-01-01
CN1440290A (zh) 2003-09-03
AU6770901A (en) 2002-01-08
HK1052300A1 (en) 2003-09-11
DE60134979D1 (de) 2008-09-04
KR100786284B1 (ko) 2007-12-18
HU227152B1 (en) 2010-08-30
GB2363983A (en) 2002-01-16
IL153541A (en) 2008-03-20
KR20030034113A (ko) 2003-05-01
US7718639B2 (en) 2010-05-18
CZ299676B6 (cs) 2008-10-15
EP1294382B1 (en) 2008-07-23
WO2002000225A1 (en) 2002-01-03
CA2414584C (en) 2009-10-27
PL200699B1 (pl) 2009-01-30
JP2004501196A (ja) 2004-01-15
PL359108A1 (en) 2004-08-23
CZ200377A3 (cs) 2003-06-18
PT1294382E (pt) 2008-10-21
AU2001267709B2 (en) 2005-07-28
IL153541A0 (en) 2003-07-06
HUP0301134A3 (en) 2006-06-28
HUP0301134A2 (hu) 2003-08-28
EP1294382A1 (en) 2003-03-26
US20030166626A1 (en) 2003-09-04
ATE401897T1 (de) 2008-08-15
CA2414584A1 (en) 2002-01-03
SI1294382T1 (sl) 2009-02-28
JP4942905B2 (ja) 2012-05-30
DK1294382T3 (da) 2008-11-24
US20100173883A1 (en) 2010-07-08
GB0016022D0 (en) 2000-08-23
NO327959B1 (no) 2009-10-26
RU2003102437A (ru) 2005-01-27
NO20026243L (no) 2003-02-27
NO20026243D0 (no) 2002-12-27
CY1108773T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
CY1105371T1 (el) Νευροπροστατευτικα 7-βητα-υδροξυστepοειδη
AU2002225849A1 (en) Distal protection and delivery system and method
AU5601300A (en) Method and compositions for treating and preventing retinal damage
AU3209000A (en) System and method for esd protection
AU6770901A (en) 7-hydroxyepiandrosterone having neuroprotective activity
IL154617A0 (en) Active equipment protection methods and apparatus
AU3068700A (en) Transportation protection device and method for producing the same
AU2003281491A1 (en) Protection pad for the tochantheric region and device comprising the pad
HK1041425A1 (en) Pedestal for protecting ornament from earthquake
AU1582801A (en) Methods and compositions for protection against bovine herpesvirus
AU7130600A (en) Functionally enhanced protective shrink-wrap coverings and methods for their manufacture and use
AU2746100A (en) Broad band controlled angle analog diffuser and associated method
AU7308300A (en) Agents for reducing cholesterol-uptake and liquid-uptake
DE60036356D1 (de) Düse sowie zugehöriger Absauger
AU1414101A (en) Neuroprotective agents and methods related thereto
AU2002227406A1 (en) Mhc class i associated peptides for prevention and treatment of tuberculosis
TW401929U (en) Device for protecting the chair back screen from being excessively raised up and damaged
AU4019100A (en) Dtpa esters with orthogonal removable protecting groups
GB9901767D0 (en) Panel damage protectors
AU1652201A (en) Device for protection of the buttocks and coccyx
TW394497U (en) Decorative and protective panel for computer case
AUPQ348899A0 (en) Therapeutic methods and uses
AUPS110202A0 (en) Arrangement for software distribution and technical support
TW411074U (en) A quickly combined and movable speaker
IL132116A0 (en) Method and means for personal protection

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130629